Chemomab Therapeutics (CMMB) PT Lowered to $30 at Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Jeff Jones lowered the price target on Chemomab Therapeutics (NASDAQ: CMMB) to $30.00 (from $42.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
